Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | No batch number | IM |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | No batch number | IM |
COVID-19; This spontaneous case, initially received on 21-Feb-2025, was reported by a non health professional and concerns an elderly male patient. At the time of the event the patient had Osteoarthritis. Concomitant medication: refer to appropriate report section. Administration of company suspect drug: On an unknown date, the patient received Flucelvax (TIV) for Influenza vaccination, Dose regimen: 0.5 ml, Route of administration: Intramuscular, Anatomical location: Not reported, Lot number: Not reported and would be requested upon follow up. Non-company suspect drugs: Novavax COVID-19 Vaccine (COVID-19 vaccine prot. subunit (NVX CoV 2373)), Indication: COVID-19 immunization. Adverse reactions/events and outcomes: On 02-Jan-2025, the patient experienced COVID-19 (outcome: Not recovered / Not resolved). experienced COVID-19 after vaccination with Novavax COVID-19 Vaccine, Adjuvanted. Lab test: SARS-COV-2 TEST on an unknown date. Flucelvax (TIV) action taken: Not Applicable Reporter's assessment: The reporter did not provide a seriousness or causality assessment; Reporter's Comments: The causality of events was related to the administration of Flucelvax (TIV)
Osteoarthritis
Tamsulosin